Eam Investors, LLC Kodiak Sciences Inc. Transaction History

Eam Investors, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 11, 2021	SELL	$110.45 - $164.47 $1.34 Million - $2 Million	-12,143 Closed	0 $0
Q4 2020 Feb 11, 2021	BUY	$60.78 - $154.03 $738,051 - $1.87 Million	12,143 New	12,143 $1.78 Million
Q3 2020 Nov 13, 2020	SELL	$45.05 - $59.27 $698,455 - $918,922	-15,504 Closed	0 $0
Q2 2020 Aug 13, 2020	SELL	$42.74 - $66.25 $986,353 - $1.53 Million	-23,078 Reduced 59.82%	15,504 $839,000
Q1 2020 May 13, 2020	BUY	$38.18 - $73.95 $192,732 - $373,299	5,048 Added 15.05%	38,582 $1.84 Million
Q4 2019 Feb 11, 2020	SELL	$13.9 - $76.65 $586,983 - $3.24 Million	-42,229 Reduced 55.74%	33,534 $2.41 Million
Q3 2019 Nov 13, 2019	BUY	$10.24 - $17.57 $775,813 - $1.33 Million	75,763 New	75,763 $1.09 Million

39M

6.5K

5.8K

Ticker KOD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 52,040,200
Market Cap $519M
Description
Kodiak Sciences Inc., a clinical stage biopharmaceutical company, researches, develops, and commercializes therapeutics to treat retinal diseases. Its lead product candidate is KSI-301, an anti-vascular endothelial growth factor antibody biopolymer that is in Phase IIb/III clinical study to treat wet age-related macular degeneration (AMD), as we...

Get notified when there are updates to the investment portfolio of Eam Investors, LLC, based on Form 13F filings with the SEC.

Stay updated on Eam Investors, LLC with notifications on news.